Fibrinogen Activity

Methodology: 
Electromagnetic endpoint detection
Performed: 
Monday - Friday
Reported: 
Within 24 hours
Use: 
This test is used to detect increased or decreased fibrinogen (factor I) concentration of acquired or congenital origin. It also monitors the severity and treatment of disseminated intravascular coagulation and fibrinolysis.
Specimen Requirements: 
Type: Plasma, sodium citrate, platelet-poor
 

Container/Tube: Light blue (3.2 percent sodium citrate)

Sample Volume: 2 mL of platelet-poor plasma (0.5 mL minimum)

Storage:
  • Ambient: 8 hours
  • Frozen: 1 month
Unacceptable Conditions:
  • Clotted or hemolyzed samples
  • EDTA plasma
  • Serum
Specimen Retention Time: 5 days
Reference Values: 
190 – 404 mg/dL
CPT Code (s): 
85384
Notes: 

Aliases

  • Factor I
  • Fibrinogen
  • Functional fibrinogen

UFHPL Test #: 50047

UFHPL Epic order code: LAB314

UFHPL - Core Laboratory Recommendations for Anticoagulant Therapy

Although the prothrombin time (PT) and activated thromboplastin time (aPTT) are both affected by vitamin K antagonists (Coumadin) and by heparin, the PT/INR is the recommended first-line assessment of Coumadin therapy.

As an alternative to aPTT measurements for unfractionated heparin, a direct heparin assay can be performed. Heparin is measured as anti-Xa units. Indeed, this is the recommended modality of assessing low molecular weight heparin therapy, since the aPTT is a poor indicator of the response to LMW heparin.

There is increasing use of direct thrombin inhibitors, such as Argatroban. We recommend monitoring the latter with the aPTT using a prolongation of approximately 1.5 to 2.5 times the baseline.

Anticoagulation therapy monitoring should be done in careful consultation with the UF Health Pharmacy and the UF Department of Medicine, Division of Hematology.
Test Directory